Zullo Investment Group Inc. Has $2.44 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Zullo Investment Group Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,847 shares of the company’s stock after selling 784 shares during the period. Johnson & Johnson accounts for 1.0% of Zullo Investment Group Inc.’s portfolio, making the stock its 21st largest holding. Zullo Investment Group Inc.’s holdings in Johnson & Johnson were worth $2,436,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. First Bank & Trust bought a new position in Johnson & Johnson in the fourth quarter worth $936,000. Hardy Reed LLC raised its holdings in shares of Johnson & Johnson by 3.9% in the fourth quarter. Hardy Reed LLC now owns 12,901 shares of the company’s stock valued at $1,866,000 after buying an additional 488 shares during the last quarter. Advyzon Investment Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth about $732,000. Handelsbanken Fonder AB increased its position in Johnson & Johnson by 2.7% in the fourth quarter. Handelsbanken Fonder AB now owns 1,541,425 shares of the company’s stock worth $222,921,000 after purchasing an additional 39,826 shares during the period. Finally, Mcdaniel Terry & Co. increased its position in Johnson & Johnson by 5.3% in the fourth quarter. Mcdaniel Terry & Co. now owns 194,783 shares of the company’s stock worth $28,170,000 after purchasing an additional 9,780 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $162.35 on Monday. The stock’s fifty day moving average price is $148.93 and its 200 day moving average price is $155.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the company posted $2.29 EPS. The business’s revenue was up 5.3% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Stifel Nicolaus decreased their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Guggenheim boosted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Finally, Raymond James decreased their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.